Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase NA 4Phase 1/2 4Phase 3 3Phase 1 3Phase 2/3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Lymphoma, Follicular 1Lymphoma 1Hodgkin Disease 1

Interventions

pembrolizumab 1interferon gamma-1b 1interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1etoposide phosphate 1camrelizumab 1aldesleukin 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Melphalan 1Lenograstim 1Interleukin-2 1Interferon-gamma 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Decitabine 1Cytarabine 1Cyclosporins 1Cyclosporine 1Carmustine 1Brentuximab Vedotin 1ABVD protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Hodgkin Disease × Carmustine × Clear all
NCT00070187 2013-10-17

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Children's Oncology Group

Phase 2/3 Completed
24 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡